P2X Purinergic Receptor Neurons

P2X Purinergic Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">P2X Purinergic Receptor Neurons</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Distribution</td>
</tr>
<tr>
<td class="label">P2X1</td>
<td>DRG, smooth muscle</td>
</tr>
<tr>
<td class="label">P2X2</td>
<td>CNS, autonomic</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>DRG,nociceptors</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>CNS, microglia</td>
</tr>
<tr>
<td class="label">P2X5</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">P2X6</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells, glia</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>gefaprixant</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Blu-4702</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CE-224545</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>P2X Involved</td>
</tr>
<tr>
<td class="label">Amyloid-β interaction</td>
<td>P2X4, P2X7</td>
</tr>
<tr>
<td class="label">Calcium dysregulation</td>
<td>All subtypes</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Memory impairment</td>
<td>P2X2, P2X4</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Elevated P2X7</td>

P2X Purinergic Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">P2X Purinergic Receptor Neurons</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Distribution</td>
</tr>
<tr>
<td class="label">P2X1</td>
<td>DRG, smooth muscle</td>
</tr>
<tr>
<td class="label">P2X2</td>
<td>CNS, autonomic</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>DRG,nociceptors</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>CNS, microglia</td>
</tr>
<tr>
<td class="label">P2X5</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">P2X6</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells, glia</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>gefaprixant</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Blu-4702</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CE-224545</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>P2X Involved</td>
</tr>
<tr>
<td class="label">Amyloid-β interaction</td>
<td>P2X4, P2X7</td>
</tr>
<tr>
<td class="label">Calcium dysregulation</td>
<td>All subtypes</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Memory impairment</td>
<td>P2X2, P2X4</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Elevated P2X7</td>
<td>Inflammation</td>
</tr>
<tr>
<td class="label">Reduced P2X2</td>
<td>Synaptic dysfunction</td>
</tr>
<tr>
<td class="label">Altered P2X4</td>
<td>Microglial activation</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Location</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>DRG, nociceptors</td>
</tr>
<tr>
<td class="label">P2X2/3</td>
<td>DRG, interneurons</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Dorsal horn</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gefaprixant</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Blu-4702</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">CE-224545</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-54179060</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-42253452</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Lipophilicity</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Structure-based design</td>
</tr>
<tr>
<td class="label">Chronic dosing</td>
<td>Slow-release formulations</td>
</tr>
<tr>
<td class="label">Side effects</td>
<td>Tissue-selective targeting</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Xenopus oocytes</td>
<td>Electrophysiology</td>
</tr>
<tr>
<td class="label">HEK293 cells</td>
<td>Pharmacology</td>
</tr>
<tr>
<td class="label">Primary neurons</td>
<td>CNS studies</td>
</tr>
<tr>
<td class="label">DRG cultures</td>
<td>Pain research</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ATP release</td>
<td>Microdialysis</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">α,β-MeATP</td>
<td>P2X1, P2X3</td>
</tr>
<tr>
<td class="label">BzATP</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Pan-P2X</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">TNP-ATP</td>
<td>P2X1-3</td>
</tr>
<tr>
<td class="label">A-438079</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">suramin</td>
<td>Pan-P2X</td>
</tr>
<tr>
<td class="label">BBG</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Selection Criteria</td>
</tr>
<tr>
<td class="label">P2X7 expression</td>
<td>Elevated in disease</td>
</tr>
<tr>
<td class="label">Pain threshold</td>
<td>P2X3 involvement</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>P2X7 activation</td>
</tr>
<tr>
<td class="label">Co-medications</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Opioids</td>
<td>Additive analgesia</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Gabapentinoids</td>
<td>Synergistic</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gefaprixant</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Blu-4702</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">JNJ-54179060</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-42253452</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">AZD-1236</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Measure</td>
</tr>
<tr>
<td class="label">Pain reduction</td>
<td>VAS score</td>
</tr>
<tr>
<td class="label">Cough frequency</td>
<td>Episodes/day</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>MMSE</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>Cytokines</td>
</tr>
<tr>
<td class="label">P2X</td>
<td>Primary Pathway</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Ca2+ influx</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Ca2+ release</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Pore formation</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>30-60%</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>4-8 hours</td>
</tr>
<tr>
<td class="label">Tmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Compartment</td>
<td>Notes</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Limited for most</td>
</tr>
<tr>
<td class="label">CSF levels</td>
<td>1-5% of plasma</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>60-80%</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">GI upset</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">ATP sensitivity (nM)</td>
<td>100</td>
</tr>
<tr>
<td class="label">Desensitization</td>
<td>Slow</td>
</tr>
<tr>
<td class="label">Ca2+ permeability</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>PNS</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>High</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>P2X</td>
</tr>
<tr>
<td class="label">Astrocyte</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>P2X4, P2X7</td>
</tr>
<tr>
<td class="label">Oligodendrocyte</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Microdialysis</td>
</tr>
<tr>
<td class="label">P2X7 autoantibody</td>
<td>Serum</td>
</tr>
</table>

P2X Purinergic Receptor Neurons are neurons that express P2X receptors, a family of ATP-gated ion channels that play crucial roles in fast synaptic transmission, pain sensing, and neurodegenerative processes. These receptor neurons are widely distributed throughout the central and peripheral nervous systems and represent important therapeutic targets for neurological disorders[@burnstock2008].

Overview

P2X receptors are cationic channels activated by extracellular adenosine triphosphate (ATP). Seven subtypes (P2X1-P2X7) have been identified, each with distinct pharmacological properties and anatomical distributions. P2X receptors mediate rapid responses to synaptic ATP release, making them critical for neural communication.

Receptor Properties

P2X Receptor Subtypes

Signaling Mechanisms

P2X receptors are ATP-gated ion channels that permit Na+ and Ca2+ influx upon activation. The signaling cascade involves[@neary2005]:

Role in Neurodegeneration

Excitotoxicity

P2X receptor overactivation contributes to excitotoxic cell death[@abbracchio2009]:

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

P2X7 receptor expression is elevated in ALS:

• Contributes to motor neuron excitotoxicity
• Mediates microglial activation
• Target for therapeutic intervention

Parkinson's Disease

• P2X7 in dopaminergic neuron death
• Neuroinflammation modulation
• Potential biomarker

Alzheimer's Disease

• Amyloid-beta interaction with P2X receptors
• Calcium dysregulation enhancement
• Synaptic dysfunction contribution

Pain Signaling

P2X receptors are critical for nociception, particularly P2X3 and P2X2/3[@ralevic2018].

Nociceptive Pathways

Therapeutic Targeting

Therapeutic Implications

Drug Development

P2X receptors are validated drug targets:

CNS Disorders

• Chronic pain: P2X3, P2X2/3 antagonists
• Neurodegeneration: P2X7 antagonists
• Mood disorders: P2X7 modulation

Cell-Type Specific Expression

Primary Sensory Neurons

• DRG neurons: P2X3, P2X2/3
• Nociceptors: P2X3 dominant
• Thermoreceptors:Mixed subtypes

Central Neurons

• Cortical neurons: P2X2, P2X4
• spinal cord neurons: P2X2, P2X5
• Hypothalamic neurons: P2X6

Glia

• Microglia: P2X7 dominant
• Astrocytes: P2X4 expression

Disease Mechanisms

Parkinson's Disease

P2X receptors play complex roles in PD pathogenesis[@chen2012]:

• P2X7 activation in substantia nigra
• Enhanced excitotoxicity
• Microglial activation
• Progressive degeneration

• Chronic microglial activation
• Cytokine release (IL-1β, TNF-α)
• Progressive neuroinflammation
• Neuronal loss amplification

• P2X7 antagonists: Neuroprotection
• P2X4 modulators: Anti-inflammatory
• Combination approaches

Alzheimer's Disease

In AD, P2X receptors contribute to pathology[@joseph2013]:

• Direct activation of P2X receptors
• Enhanced calcium influx
• Synaptic dysfunction
• Memory impairment

• P2X7 antagonists: Reduce neuroinflammation
• P2X4 modulators: Protect synapses
• P2X2/4 agonists: Enhance cognition

• CSF P2X7 levels: Disease monitoring
• Peripheral blood markers: Screening

Amyotrophic Lateral Sclerosis

P2X receptors are involved in ALS:

• P2X7 upregulation in motor neurons
• Excitotoxic cell death
• Impaired glutamate clearance

• Chronic activation via P2X7
• Pro-inflammatory cytokine release
• Non-cell autonomous degeneration

• P2X7 antagonists in development
• Gene therapy approaches
• Combined neuroprotection

Multiple Sclerosis

In demyelinating diseases:

• P2X7-mediated death
• Myelin breakdown
• Axonal injury

• P2X7 blockade: Neuroprotection
• Remyelination promotion

Psychiatric Disorders

P2X receptors are emerging targets in psychiatry[@wu2019]:

Depression

• P2X7 in serotonin release
• Dopamine modulation
• Mood regulation

• Cytokine-induced P2X7 activation
• Depression behavior
• Treatment resistance

• P2X7 antagonists in Phase 2
• Treatment-resistant depression
• Bipolar depression

Anxiety

P2X receptors in anxiety:

• P2X7: Anxiogenic effects
• P2X4: Anxiolytic potential
• Receptor-selective targeting

Schizophrenia

Findings in schizophrenia[@suarez2019]:

• P2X7 polymorphisms associated
• P2X4 expression changes
• Cognitive deficits link

Epilepsy

P2X receptors in seizure disorders[@frank2014]:

Mechanisms

• ATP release during seizures
• P2X receptor activation
• Hyperexcitability

• Network synchronization
• Activity propagation

• P2X antagonists: Anticonvulsant
• P2X2/3: Modulation

Status Epilepticus

In prolonged seizures:

• P2X7-mediated neurodegeneration
• Therapeutic intervention potential

Pain Signaling Mechanisms

Nociception

P2X3 and P2X2/3 are primary pain receptors[@muller2018]:

Neuropathic Pain

P2X4 underlies neuropathic pain[@barber2014]:

• Spinal cord microglia
• BDNF release
• Neuronal dysregulation

• Enhanced excitability
• Central sensitization

• P2X4 antagonists
• Microglial inhibition

Inflammatory Pain

P2X7 in inflammatory pain:

• Cytokine release
• Hyperalgesia
• Therapeutic targeting

Drug Development

Clinical Candidates

Challenges

Future Directions

• P2X3 antagonists
• P2X4 modulators
• P2X7 allosteric modulators

• P2X + opioid
• P2X + gabapentinoid
• Receptor-selective approaches

Research Models

In Vitro Models

In Vivo Models

• Knockout mice: P2X7-/-, P2X3-/-
• Transgenic: overexpression
• Conditional: cell-type specific

Biomarkers

Pharmacological Properties

Agonists

Antagonists

Structure-Activity

Key structural features for antagonism:

• Hydrophobic core
• Polar head groups
• Hydrogen bonding
• Receptor subtypes selectivity

Clinical Considerations

Patient Selection

Monitoring

• Efficacy: Pain scores, inflammation markers
• Safety: Liver function, blood counts
• Biomarkers: ATP levels, receptor expression

Drug Interactions

See Also

• [Purinergic Signaling](/mechanisms/purinergic-signaling)
• [Serotonin 5-HT2A Receptor Neurons](/cell-types/serotonin-5-ht2a-receptor-neurons)
• [Motor Neurons](/cell-types/motor-neurons-als)
• [Cholinergic Hypothesis AD](/mechanisms/cholinergic-hypothesis-ad)

References

Therapeutic Implications and Drug Development

Drug Development Pipeline

Current P2X receptor-targeted drugs in development:

Mechanisms of Drug Action

• Block ATP-mediated pain signaling
• Reduce peripheral sensitization
• Decrease CNS hyperexcitability

• Inhibit microglial activation
• Reduce cytokine release
• Protect neurons from excitotoxicity

• Balance microglial function
• Reduce neuropathic pain
• Improve cognitive function

Clinical Trial endpoints

Molecular Pharmacology

Receptor Structure

P2X receptors are trimeric ion channels:

• Two transmembrane domains
• Extracellular ATP-binding domain
• Intracellular N- and C-termini

• Permable to Na+, K+, Ca2+
• Rapid desensitization (P2X3)
• Sustained activation (P2X7)

• Conformational changes
• Channel opening
• Ion flux regulation

Signaling Cascades

Pharmacokinetics

Absorption

Distribution

Metabolism and Elimination

• Metabolism: Liver (CYP450)
• Excretion: Renal (60-80%)
• Active metabolites: Some

Adverse Effects

Common Side Effects

Serious Concerns

• Liver toxicity: Monitor function
• Immunosuppression: Infection risk
• Bleeding: Platelet function

Contraindications

• Pregnancy: Insufficient data
• Liver disease: Avoid
• Severe renal disease: Caution

Comparative Pharmacology

P2X Receptor Subtype Selectivity

Therapeutic Index

Neurobiology

Synaptic Transmission

P2X receptors in synaptic function:

• ATP as co-transmitter
• Rapid postsynaptic responses
• Receptor recycling

• Presynaptic modulation
• Activity-dependent release
• Plasticity mechanisms

• Oscillation regulation
• Rhythm generation
• Information processing

Glial-Neuronal Communication

P2X receptors mediate glia-neuron signaling:

Biomarkers and Diagnostics

Clinical Biomarkers

Diagnostic Applications

• P2X7 expression levels
• ATP release capacity
• Receptor function

• Drug efficacy markers
• Target engagement
• Side effect prediction

• Disease progression
• Treatment response
• Survival indicators

See Also